• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    5/24/24 4:31:11 PM ET
    $ACRS
    $ADIL
    $BCLI
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACRS alert in real time by email

    Gainers

    • Sharps Technology (NASDAQ:STSS) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million.
    • Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares increased by 9.75% to $2.25. The market value of their outstanding shares is at $3.2 million.
    • Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 6.89% to $0.93. The market value of their outstanding shares is at $1.6 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by 6.4% to $1.33. The company's market cap stands at $5.6 million.
    • Aclaris Therapeutics (NASDAQ:ACRS) shares rose 5.4% to $1.17. The market value of their outstanding shares is at $83.3 million.
    • Brainstorm Cell (NASDAQ:BCLI) shares moved upwards by 4.98% to $0.56. The market value of their outstanding shares is at $39.5 million.

    Losers

    • DIH Holding US (NASDAQ:DHAI) stock fell 24.4% to $1.21 during Friday's after-market session. The market value of their outstanding shares is at $49.0 million.
    • Innovative Eyewear (NASDAQ:LUCY) stock fell 14.04% to $0.84. The market value of their outstanding shares is at $14.7 million.
    • SCWorx (NASDAQ:WORX) shares decreased by 9.1% to $1.8. The company's market cap stands at $2.1 million.
    • 60 Degrees (NASDAQ:SXTP) stock fell 7.75% to $0.29. The market value of their outstanding shares is at $3.5 million.
    • OneMedNet (NASDAQ:ONMD) shares decreased by 7.4% to $2.13. The company's market cap stands at $50.8 million.
    • iSpecimen (NASDAQ:ISPC) stock decreased by 7.18% to $0.29. The company's market cap stands at $2.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $ADIL
    $BCLI
    $CYCC

    CompanyDatePrice TargetRatingAnalyst
    Aclaris Therapeutics Inc.
    $ACRS
    7/10/2025$6.00Overweight
    Piper Sandler
    Aclaris Therapeutics Inc.
    $ACRS
    5/28/2025$8.00Outperform
    Wedbush
    Aclaris Therapeutics Inc.
    $ACRS
    3/18/2025Overweight
    Cantor Fitzgerald
    Aclaris Therapeutics Inc.
    $ACRS
    12/23/2024$20.00Neutral → Buy
    H.C. Wainwright
    Aclaris Therapeutics Inc.
    $ACRS
    11/20/2024Neutral → Overweight
    Cantor Fitzgerald
    Aclaris Therapeutics Inc.
    $ACRS
    11/19/2024$2.00 → $7.00Market Perform → Outperform
    Leerink Partners
    Aclaris Therapeutics Inc.
    $ACRS
    11/19/2024$8.00Neutral → Buy
    BTIG Research
    Aclaris Therapeutics Inc.
    $ACRS
    11/19/2024$2.00 → $7.00Hold → Buy
    Jefferies
    More analyst ratings

    $ACRS
    $ADIL
    $BCLI
    $CYCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler resumed coverage on Aclaris Therapeutics with a new price target

    Piper Sandler resumed coverage of Aclaris Therapeutics with a rating of Overweight and set a new price target of $6.00

    7/10/25 8:47:17 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wedbush initiated coverage on Aclaris Therapeutics with a new price target

    Wedbush initiated coverage of Aclaris Therapeutics with a rating of Outperform and set a new price target of $8.00

    5/28/25 8:54:54 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald resumed coverage on Aclaris Therapeutics

    Cantor Fitzgerald resumed coverage of Aclaris Therapeutics with a rating of Overweight

    3/18/25 8:23:58 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADIL
    $BCLI
    $CYCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Balthaser Kevin converted options into 2,375 shares and covered exercise/tax liability with 677 shares, increasing direct ownership by 0.91% to 187,453 units (SEC Form 4)

    4 - Aclaris Therapeutics, Inc. (0001557746) (Issuer)

    3/3/26 4:10:13 PM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Falconx Holdings Ltd sold $1,490,755 worth of shares (769,320 units at $1.94) and exercised 461,538 in-the-money shares at a strike of $0.00 (SEC Form 4)

    4 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:45:04 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    New insider Falconx Holdings Ltd claimed ownership of 769,230 shares (SEC Form 3)

    3 - Sharps Technology Inc. (0001737995) (Issuer)

    2/13/26 4:10:05 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $ACRS
    $ADIL
    $BCLI
    $CYCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Gross Harrison R. bought $1,980 worth of shares (1,500 units at $1.32), increasing direct ownership by 12% to 13,733 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/22/26 11:29:05 AM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Financial Officer Gayle Oswald bought $1,669 worth of shares (1,000 units at $1.67), increasing direct ownership by 54% to 2,865 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/15/26 5:00:07 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Chief Executive Officer Gross Harrison R. bought $2,400 worth of shares (1,500 units at $1.60), increasing direct ownership by 14% to 12,233 units (SEC Form 4)

    4 - Innovative Eyewear Inc (0001808377) (Issuer)

    1/12/26 5:00:39 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    $ACRS
    $ADIL
    $BCLI
    $CYCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OneMedNet and Navidence Announce Strategic Collaboration: Empowering Pharma with Precision Real-World Data Insights

    MINNEAPOLIS, March 18, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-ready Real-World Data (RWD), today announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. What This Collaboration Means for the Pharma Market Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence's platform enables precise definition of health data needs via Computable Operationa

    3/18/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

    FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut ExtractCompany has signed an option agreement with Florida State University (FSU) to license a capsule formulation, expanding on its recent exercise of a license option for large-scale production WASHINGTON, March 18, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced it submitted a New Dietary Ingredient Notification (NDIN) to the U.S. Food and Drug Admi

    3/18/26 8:01:00 AM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADIL
    $BCLI
    $CYCC
    SEC Filings

    View All

    SEC Form 424B5 filed by 60 Degrees Pharmaceuticals Inc.

    424B5 - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:17:36 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    60 Degrees Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - 60 DEGREES PHARMACEUTICALS, INC. (0001946563) (Filer)

    3/13/26 5:15:16 PM ET
    $SXTP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iSpecimen Inc. filed SEC Form 8-K: Other Events

    8-K - iSpecimen Inc. (0001558569) (Filer)

    3/13/26 5:00:30 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ACRS
    $ADIL
    $BCLI
    $CYCC
    Leadership Updates

    Live Leadership Updates

    View All

    Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

    - Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has completed patient enrollment in its randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug (ATI-045) in patients with moderate-to-severe atopic dermatitis (AD). Top line results are expected in the fourth quarter of 2026. "The strong interest in participating in this Phase 2 trial reflects the urgent need for innovative solutions in atopic dermatitis and the excitement surrou

    3/18/26 6:55:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DIH Announces Fiscal 2025 Fourth Quarter and Fiscal Year End Financial Results

    NORWELL, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH" or the "Company") (NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced financial results for the fiscal 2025 fourth quarter and fiscal year ended March 31, 2025. Recent Highlights Revenue of $62.9 million for the fiscal year ended March 31, 2025, representing a decrease of 2.5% over the prior year Device revenue of $49.7

    10/20/25 5:05:09 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    DIH Appoints Barrett Mooney, Ph.D to DIH Holding US, Inc. Board of Directors

    NORWELL, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. ("DIH")(NASDAQ:DHAI), a global provider of advanced robotic devices used in rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions, today announced the appointment of Barrett Mooney, Ph.D. to its Board of Directors. Barrett Mooney, Ph.D., has an extensive track record of growing complex and manufacturing related businesses. He currently provides strategic advisory services to growing high-technology private and public compan

    9/8/25 4:46:27 PM ET
    $DHAI
    Medical/Dental Instruments
    Health Care

    $ACRS
    $ADIL
    $BCLI
    $CYCC
    Financials

    Live finance-specific insights

    View All

    Innovative Eyewear, Inc. Announces Q4 and Full Year 2025 Earnings Conference Call

    MIAMI, March 10, 2026 /PRNewswire/ -- Innovative Eyewear, Inc. ("Innovative Eyewear" or the "Company") (NASDAQ: LUCY; LUCYW), the developer & manufacturer of smart eyewear under the Lucyd®, Lucyd Armor®, Reebok®, Nautica®, and Eddie Bauer® brands, today announced its upcoming earnings conference call to share the Company's key operational and financial results for the fiscal year ended December 31, 2025. Earnings Call DetailsDate: Tuesday, March 31, 2026Time: 12:00 PM ETParticipant Listening OptionsInterested participants can join the event by using the dial-in numbers, or by cl

    3/10/26 4:30:00 PM ET
    $LUCY
    Ophthalmic Goods
    Health Care

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model -  WAYNE, Pa., Feb. 26,

    2/26/26 6:58:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclaris Therapeutics Announces Positive Interim Results of Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Supporting Expedited Clinical Development

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial Reinforce Potential Best-in-Class Potency Advantage of ATI-052 - - Trial Results Support Potential for Extended Dosing of up to Every Three Months - - Initiation of Phase 1b Proof-of-Concept (POC) Trials in Atopic Dermatitis (AD) and Asthma Now Expected in First Quarter of 2026; Planning Underway for Advancement of ATI-052 into Phase 2b Trial in AD in the Second Half of 2026 - - Management to Host a Conference Call to Discuss Update Today at 8:00 AM EST - WAYNE, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on

    1/6/26 6:59:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACRS
    $ADIL
    $BCLI
    $CYCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    12/5/24 7:17:43 AM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by SCWorx Corp.

    SC 13G - SCWorx Corp. (0001674227) (Subject)

    11/26/24 5:02:01 PM ET
    $WORX
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form SC 13G filed by Aclaris Therapeutics Inc.

    SC 13G - Aclaris Therapeutics, Inc. (0001557746) (Subject)

    11/25/24 11:02:19 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care